Mr. Sebastien Plouffe reports

DEFENCE LAUNCHES ACCUM COMBINED WITH ACTINIUM-225 TO INCREASE EFFICACY AND SAFETY OF RADIO-IMMUNOCONJUGATE CANCER THERAPIES

Defence Therapeutics Inc. has arranged a collaboration with the Canadian Nuclear Laboratories. CNL, Canada's premier nuclear science facility, will conduct preclinical studies combining radiotherapy alpha-particle actinium-225 (Ac-225) with Defence's proprietary Accum delivery technology.

Targeted radiotherapies using Ac-225 have shown great promise in cancer treatment. Ac-225 emits powerful alpha particles that irreparably damage cancer cells' DNA, leading to cell death. Ac-225 is typically attached to cancer-targeting antibodies. However, many of these Ac-225-antibody complexes become trapped in cellular compartments called endosomes, preventing them from reaching the cell's nucleus where they can be most effective. Defence's Accum technology is designed to enhance the escape of these complexes from endosomes, improving their accumulation in the nucleus. This approach could reduce the required dosage levels of Ac-225, potentially minimizing side effects while maintaining therapeutic efficacy.

The Ac-225 will be produced and supplied by CNL from its Th-229/Ac-225 generator at Chalk River Laboratories. CNL will evaluate several tumour-targeting antibodies modified with Accum technology to transport Ac-225. Studies in rodent models will assess the biodistribution, therapeutic potency and safety profile of these selected radiolabelled antibodies. The research aims to determine how effectively the Accum-modified antibodies deliver Ac-225 to cancer cells and their impact on tumour growth. This collaboration marks a significant step in Defence's mission to revolutionize cancer treatment through enhanced targeted therapies. By combining CNL's expertise in Ac-225 radioisotope and R&D (research and development) in targeted alpha therapy with Defence's innovative delivery technology, the project seeks to overcome current limitations in radioisotope-based cancer treatments.

"We believe Accum will significantly enhance the potency of Ac-225 immuno-conjugates by improving therapeutic efficacy and tumour targeting. Our technology's ability to facilitate endosomal escape and increase the presence of therapeutics in cell nuclei enhances the effectiveness of alpha-particles at their primary target. Our team is confident this innovative approach will overcome current limitations in radioisotope delivery for oncology, amplifying anti-cancer effects while reducing off-target toxicity. The synergy between Accum and CNL's expertise will advance precision oncology, leading to more effective and safer treatments," said Sebastien Plouffe, chief executive officer and founder of Defence Therapeutics.

As the project progresses, Defence will provide updates on the development of these Accum-enhanced radio-immuno-conjugates. With the global radiopharmaceutical market projected to reach $16.87-billion (U.S.) by 2033, Defence is well positioned to contribute to this rapidly growing field of precision oncology.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC (antibody-drug conjugate) products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the Accum technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illnesses such as cancer and infectious diseases.

We seek Safe Harbor.